Related Experiment Video

Updated: Aug 13, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Inhibition of autophosphorylation of epidermal growth factor receptor by small peptides in vitro

Mineo Abe1, Yoshihiro Kuroda, Munetaka Hirose

  • 1Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.

British Journal of Pharmacology
|January 13, 2006
PubMed

Insights

Novel oligopeptides targeting epidermal growth factor receptor (EGFR) autophosphorylation sites show promise for treating breast and lung cancers. These synthetic peptides effectively inhibit EGFR activity, offering a potential new therapeutic strategy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Uncontrolled epidermal growth factor receptor (EGFR) signaling drives breast and lung cancers.
  • Targeting EGFR autophosphorylation sites is a therapeutic strategy.
  • Oligopeptides designed from EGFR autophosphorylation sites may act as inhibitors.

Purpose of the Study:

  • To design and evaluate synthetic oligopeptides that inhibit EGFR autophosphorylation.
  • To assess the potential of these peptides as therapeutic agents for EGFR-driven cancers.

Main Methods:

  • Synthetic oligopeptides based on EGFR autophosphorylation sites (Y1068, Y1148, Y1173, Y992) were designed.
  • Purified EGFR was phosphorylated in vitro with EGF and tested peptides.
  • Phosphorylation levels were quantified using SDS-PAGE and Western blot analysis.

Main Results:

  • Peptides Ac-VPEYINQ-NH2 (Y1068) and Ac-DYQQD-NH2 (Y1148) demonstrated potent inhibition (30-50% suppression at 4 mM).
  • A combination of peptides targeting Y1068, Y1148, and Y1173 showed synergistic inhibition, with an IC50 of 0.5 mM.
  • Peptides derived from insulin receptor sites did not inhibit EGFR, suggesting specificity.

Conclusions:

  • Oligopeptides derived from EGFR autophosphorylation sites can effectively inhibit EGFR autophosphorylation.
  • These peptides exhibit specificity for EGFR.
  • The designed peptides represent a promising foundation for developing novel cancer therapeutics for breast and lung cancers.

More Related Videos

A Functional Assay for Gap Junctional Examination; Electroporation of Adherent Cells on Indium-Tin Oxide11:02

A Functional Assay for Gap Junctional Examination; Electroporation of Adherent Cells on Indium-Tin Oxide

Published on: October 18, 2014

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...